1887

Chapter 11 : Cell Lines: Applications and Biosafety

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Zoom in
Zoomout

Cell Lines: Applications and Biosafety, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555815899/9781555813390_Chap11-1.gif /docserver/preview/fulltext/10.1128/9781555815899/9781555813390_Chap11-2.gif

Abstract:

The early use of continuous cell lines (CCLs) for the manufacture of biological products is represented by the manufacture of foot-and-mouth disease vaccine in the Syrian hamster cell line baby hamster kidney (BHK), the production of interferon from the B-lymphoblastoid cell line Namalwa, and the introduction of monoclonal antibodies from hybridoma cells. Long-standing experience has shown that contamination with pathogenic agents is the most important hazard and merits careful assessment of safety precautions. The culture types, in order of decreasing risk, are primary cell cultures; CCLs; and intensively characterized cells, including human diploid fibro-blasts. Most national guidelines recommend that human and other primate cells be handled using biosafety level 2 practices and containment and that all work be performed in a biosafety cabinet (BSC). For airfreight, cell cultures have been classified as ‘’diagnostic specimens’’ under the International Air Transport Association (IATA) regulations. In many cases gene therapy concepts are based on viral vectors (e.g., adenoviruses and retroviruses). This chapter describes safety measures for large-scale production of biologicals, and focuses on characterization of cell lines. PCR is now commonly used to identify cell lines and to detect both cross contamination by other cell lines and contamination by adventitious agents or in combination with other methods. Safety testing of cells used in the manufacture of biologicals is usually performed with procedures accredited to good laboratory practice.

Citation: Doblhoff-Dier O, Stacey G. 2006. Cell Lines: Applications and Biosafety, p 221-240. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch11

Key Concept Ranking

Restriction Fragment Length Polymorphism
0.42507088
Random Amplified Polymorphic DNA
0.42055815
Herpes simplex virus 1
0.41932473
0.42507088
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555815899.ch11
1. Adamson, S. R. 1998. Experiences of virus, retrovirus and retrovirus-like particles in Chinese hamster ovary (CHO) and hybridoma cells used for production of protein therapeutics. Dev. Biol. Stand. 93:8996.
2. Alper, T.,, W. A. Cramp,, D. A. Haig, and, M. C. Clarke. 1967. Does the agent of scrapie replicate without nucleic acid? Nature 214:764766.
3. Anson, D. S.,, G. J. Smith, and, D. W. Parsons. 2006. Gene therapy for cystic fibrosis airway disease—is clinical success imminent? Curr. Gene Ther. 6:161179.
4. Bulychev, A.,, A. Trouet, and, P. Tulkens. 1978. Uptake and intracellular distribution of neutral red in cultured fibroblasts. Exp. Cell Res. 115:343355.
5. Butler, M. 1991. The characteristics and growth of cultured cells, p. 1–25. In M. Butler (ed.), Mammalian Cell Biotechnology: a Practical Approach. IRL Press, Oxford, United Kingdom.
6. Calvez, V.,, O. Rixe,, P. Wang,, R. Mouawad,, C. Soubrane,, A. Ghoumari,, O. Verola,, D. Khayat, and, F. Colbere-Garapin. 1996. Virus-free transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment induces tumor cell death. Clin. Cancer Res. 1:4751.
7. Centers for Disease Control and Prevention and National Institutes of Health. 1999. Biosafety in Microbiological and Biomedical Laboratories, 4th ed. U.S. Government Printing Office, Washington, D.C.
8. Chen, T. C. 1998. Identity testing, authentication, karyology, p. 9A:1.1–9A:1.20. In A. Doyle,, J. B. Griffiths, and, D. G. Newell (ed.), Cell & Tissue Culture: Laboratory Procedures. John Wiley & Sons, Ltd., Chichester, United Kingdom.
9. CHMP/CVMP. 2001. Note for guidance on minimising risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products. EMEA/401/01—final. [Online.] http://www.emea/eu/int.
10. Coecke, S.,, M. Balls,, G. Bowe,, J. Davis,, G. Gstraunthaler,, T. Hartung,, R. Hay,, O.-W. Merten,, A. Price,, L. Shechtman,, G. N. Stacey, and, W. Stokes. 2005. Guidance on Good Cell Culture Practice. A report of the second ECVAM Task Force on Good Cell Culture Practice. ATLA 33:1-27. [Online.] http://www.nibsc.ac.uk/documents/CBI/GCCP%20TF%20Report%20PD% 20for%20open%20release%2013%20June%2005.pdf
11. Committee for Proprietary Medicinal Products Ad Hoc Working Party on Biotechnology/Pharmacy Working Party on Safety Medicines. 1991. EEC regulatory document. Note for guidance: validation of virus removal and inactivation procedures. Biologicals 19:247251.
12. Cooney, C. L. 1995. Are we prepared for animal cell technology in the 21st century? Cytotechnology 18:38.
13. Davidson, W. L., and, K. Hummler. 1960. B-virus infection in man. Ann. N. Y. Acad. Sci. 85:99709979.
14. Dragunsky, E.,, K. Chumakov,, L. Norwood,, M. Parker,, Z. Lu, and, Y. Ran. 1993. Live polio vaccine reversion: impact of cell density. In Vitro 3(2):123A.
15. Ende, N., and, R. Chen. 2002. Parkinson’s disease mice and human umbilical cord blood. J. Med. 33:173180.
16. Ende, N.,, R. Chen, and, A. Reddi. 2004. Transplantation of human umbilical cord blood cells improves glycemia and glomerular hypertrophy in type 2 diabetic mice. Biochem. Biophys. Res. Commun. 321:168171.
17. Erickson, G. A.,, S. R. Bolin, and, J. D. Landgraf. 1991. Viral contamination of fetal bovine serum used for tissue culture: risks and concerns. Dev. Biol. Stand. 75:173175.
18. Fairchild, P. J.,, S. Cartland,, K. Nolan, and, H. Waldmann. 2004. Embryonic stem cells and the challenge of transplantation tolerance. Trends Immunol. 25:465470.
19. Frommer, W.,, L. Archer,, B. Boon,, G. Brunius,, C. H. Collins,, P. Crooy,, O. Doblhoff-Dier,, R. Donikian,, J. Economidis,, C. Frontali,, T. Gaal,, S. Hamp,, H. Haymerle,, E. H. Houwink,, M. T. Küenzi,, P. Krämer,, H. L. M. Lelieveld,, M. T. Logtenberg,, J. Lupker,, S. Lund,, J. L. Mahler,, C. Mosgaard,, F. Normand-Plessier,, F. Rudan,, R. Simon,, G. Tuijenburg Muijs,, S. P. Vranch, and, R. G. Werner. 1993. Safe biotechnology (5). Recommendations for safe work with animal and human cell cultures concerning potential human pathogens. Appl. Microbiol. Biotechnol. 39:141147.
20. Garnick, R. L. 1998. Raw materials as a source of contamination in large scale culture. Dev. Biol. Stand. 93:2129.
21. Gilbert, D. A.,, Y. A. Reid,, M. H. Gail,, D. Pee,, C. White,, R. J. Hay, and, S. J. O’Brien. 1991. Application of DNA fingerprints for cell line individualisation. Am. J. Hum. Genet. 47:499514.
22. Global Programme for Vaccines and Immunization. 1997. The WHO Guide to Good Manufacturing Practice (cGMP) Requirements. World Health Organization, Geneva, Switzerland.
23. Griffith, J. S. 1967. Self-replication and scrapie. Nature 215:10431044.
24. Griffiths, B. 1991. Products from animal cells, p. 207–235. In M. Butler (ed.), Mammalian Cell Biotechnology: a Practical Approach. IRL Press, Oxford, United Kingdom.
25. Grun, J. B.,, E. M. White, and, A. F. Sito. 1992. Virus removal/inactivation by purification of biopharmaceuticals. Biopharm. Manuf. 5:2230.
26. Gugel, E. A., and, M. E. Sanders. 1986. Needle-stick transmission of human colonic adenocarcinoma. N. Engl. J. Med. 315:1487. (Letter.)
27. Human Medicines Evaluation Unit. 1997. ICH Topic Q 5 D—Quality of Biotechnological Products: Derivation and Characterisation of Cell Substrates used for Production of Biotechnological/Biological Products. European Agency for the Evaluation of Medicinal Products, ICH Technical Co-ordination, London, United Kingdom.
28. Imler, J. L.,, M. Mehtali, and, A. Pavirani. 1994. Development aspects of recombinant adenovirus production. Gene Ther. 1:7.
29. International Association of Microbiological Societies. 1963. Proceedings: Symposium on the Uses of Human Diploid Cell Strains. Blasnikova-Tiskarna, Lubliana, Zagreb, Croatia.
30. Jank, B.,, H. Haymerle, and, O. Doblhoff-Dier. 1996. Zurich hazard analysis in biotechnology. Nat. Biotechnol. 14:894896.
31. Jeffreys, A. J.,, V. Wilson, and, S. L. Thein. 1985a. Hypervariable ‘minisatellite’ regions in human DNA. Nature 314:6773.
32. Jeffreys, A. J.,, V. Wilson, and, S. L. Thein. 1985b. Individual-specific ‘fingerprints’ of human DNA. Nature 316:7679.
33. Jiang, Y.,, B. Vaessen,, T. Lenvik,, M. Blackstad,, M. Reyes, and, C. Verfaillie. 2002a. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle and brain. Exp. Hematol. 30:896904.
34. Jiang, Y.,, B. N. Jahagirdar,, R. L. Reinhardt,, R. E. Schwartz,, C. D. Keene,, X. R. Ortiz-Gonzalez,, M. Reyes,, T. Lenvik,, T. Lund,, M. Blackstad,, J. Du,, S. Aldrich,, A. Lisberg,, W. C. Low,, D. A. Largaespada, and, C. M. Verfaillie. 2002b. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:4149.
35. Kajander, E. O., and, N. Ciftcioglu. 1998. Nanobacteria: an alternative mechanism for pathogenic intra- and extracellular calcification and stone formation. Proc. Natl. Acad. Sci. USA 95:82748279.
36. Kassem, M.,, M. Kristiansen, and, B. Abdallah. 2004. Mesenchymal stem cells: cell biology and potential use in therapy. Basic Clin. Pharmacol. Toxicol. 95:209214.
37. Lessa, E. P., and, G. Applebaum. 1993. Screening techniques for detecting allelic variation in DNA sequences. Mol. Ecol. 2:119129.
38. Lloyd, G., and, N. Jones. 1984. Infection of laboratory workers with hantavirus acquired from immunocytomas propagated in laboratory rats. J. Infect. Dis. 12:117125.
39. Lower, J. 1995. Acceptability of continuous cell lines for the production of biologics. Cytotechnology 18:1520.
40. Lubiniecki, A. S. 1995. Biotechnology products from animal cells. In Vitro 31:4A.
41. Meager, A., and, E. Griffiths. 1994. Human somatic gene therapy. Trends Biotechnol. 12:108113.
42. Miller, A. D. 1990. Retrovirus packaging cell lines. Hum. Gene Ther. 1:514.
43. Miller, S. R., and, D. Bergmann. 1993. Biocontainment design considerations for pharmaceutical facilities. J. Ind. Microbiol. 11:223234.
44. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:5563.
45. Nakamura, S.,, T. Shimazaki,, K. Sakamoto,, A. Fukusho,, Y. Inoue, and, N. Ogawa. 1995. Enhanced replication of orbiviruses in bovine testicular cells infected with bovine viral diarrhoea virus. J. Vet. Med. Sci. 57:677681.
46. National Research Council. 1989. Prudent Practices for the Handling and Disposal of Infectious Material, p. 13–33. National Academy Press, Washington, D.C.
47. Navasaria, H. A.,, S. R. Myers,, I. M. Leigh, and, I. A. McKay. 1995. Culturing skin in vitro for wound therapy. Trends Biotechnol. 13:91100.
48. Nicklas, W.,, V. Kraft, and, B. Meyer. 1993. Contamination of transplanted tumours, cell lines and monoclonal antibodies with rodent viruses. Lab. Anim. Sci. 43:296300.
49. Nims, R. W.,, A. P. Shoemaker,, M. A. Bauernschub,, L. J. Rec, and, J. W. Harbell. 1998. Sensitivity of isoenzyme analysis for the detection of interspecies cell line cross-contamination. In Vitro Cell Dev. Biol. Anim. 34:3539.
50. O’Brien, S. J.,, J. E. Shannon, and, M. H. Gail. 1980. A molecular approach to the identification and individualization of human and animal cells in culture: isozyme and allozyme genetic signatures. In Vitro 16:119135.
51. OECD Expert Group on Good Laboratory Practice. 1982. Good Laboratory Practice in the Testing of Chemicals. Organisation of Economic Co-operation and Development, Paris, France.
52. Ohe, Y.,, D. Zhao,, N. Saijo, and, E. R. Podack. 1995. Construction of a novel bovine papilloma virus vector without detectable transforming activity suitable for gene therapy. Hum. Gene Ther. 6:325333.
53. Onyekaba, C.,, J. Fahrmann,, L. Bueon,, P. King, and, S. M. Goyal. 1987. Comparison of five cell lines for the propagation of bovine viral diarrhea and infectious bovine rhinotraecheitis viruses. Microbiologica 10:311315.
54. Ostrove, J. M. 1994. Safety testing programs for gene therapy viral vectors. Cancer Gene Ther. 1:125131.
55. Perkowski, C. A. 1990. Operational aspects of bioreactor contamination control. J. Parenteral Sci. Technol. 44:113117.
56. Petricciani, J. C. 1995. The acceptability of continuous cell lines: an historical perspective. Cytotechnology 18:313.
57. Poiley, J. A.,, S. T. Bierley,, T. Hillesund, R. E. Nelson, T. M. Monticello, and, R. Raineri. 1994. Methods for estimating retroviral burden. Biopharm. Manuf. 7:3235.
58. Prusiner, S. B. 1982. Novel proteinaceous infectious particles cause scrapie. Science 216:136144.
59. Prusiner, S. B.,, J. Collinge,, J. Powell, and, B. Anderton (ed.). 1992. Prion Diseases of Humans and Animals. Ellis Horwood, London, United Kingdom.
60. Pyra, H.,, J. Boni, and, J. Schupach. 1994. Ultrasensitive retrovirus detection by a reverse transcriptase assay based on product enhancement. Proc. Natl. Acad. Sci. USA 91:15441548.
61. Roberts, P. 1994. Virus safety in bioproducts. J. Chem. Technol. Biotechnol. 59:110.
62. Saib, A.,, J. Peries, and, H. de The. 1995. Recent insights into the biology of the human foamy virus. Trends Microbiol. 3:173178.
63. Schaeffer, W. I. 1990. Nomenclature of cells in culture. In Vitro 26:97101.
64. Sito, A. F. 1993. Removal and inactivation of model viruses by methods commonly used in purification of biopharmaceuticals. J. Cell. Biochem. 46:46.
65. Stacey, G. N.,, B. J. Bolton, and, A. Doyle. 1991. The quality control of cell banks using DNA fingerprinting. EXS 58:361370.
66. Stacey, G. N.,, H. Hoelzl,, J. R. Stephenson, and, A. Doyle. 1997. Authentication of animal cell cultures by direct visualisation of DNA, aldolase gene PCR and isoenzyme analysis. Biologicals 25:7583.
67. Stacey, G. N., and, P. Phillips. 1999. Quality assurance for cell substrates. Dev. Biol. Stand. 98:141152.
68. Thomson, J. A.,, J. Itskovitz Eldor, S. S. Shapiro,, M. A. Waknitz,, J. J. Swiergiel,, V. S. Marshall, and, J. M. Jones. 1998. Embryonic stem cell lines derived from human blastocysts. Science 282:11451147.
69. Urnovitz, H. B., and, W. H. Murphy. 1996. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin. Microbiol. Rev. 9:7299.
70. U.S. Food and Drug Administration. 1996. Addendum to The Points to Consider in Human Somatic Cell and Gene Therapy. Hum. Gene Ther. 7:11811190.
71. Vassart, G.,, M. Georges,, R. Monsieur,, H. Brocas,, A. S. Lequarre, and, D. Christophe. 1987. A sequence in M13 phage detects hypervariable minisatellites in human and animal DNA. Science 235:683684.
72. Vilcek, S.,, A. J. Herring,, J. A. Herring,, P. F. Nettleton,, J. P. Lowings, and, D. J. Paton. 1994. Pestiviruses isolated from pigs, cattle and sheep can be allocated into at least three genogroups using polymerase chain reaction and restriction endonuclease analysis. Arch. Virol. 136:309323.
73. Wagner, J., and, J. Barker. 2004. Umbilical cord blood transplantation: novel approaches toward improving engraftment. Biol. Blood Marrow Transplant. 10:733.
74. Wagner, J., and, C. Verfaillie. 2004. GMP manufacture of the multipotent adult progenitor cell (MAPC) and strategy for clinical testing. Biol. Blood Marrow Transplant. 10:738.
75. Webb, M. B., and, P. G. Debenham. 1992. Cell line characterization by DNA fingerprinting; a review. Dev. Biol. Stand. 76:3942.
76. Weissmahr, R. N.,, J. Schupbach, and, J. Boni. 1997. Reverse transcriptase activity in chicken embryo fibroblast culture supernatants is associated with particles containing endogenous avian retrovirus EAV-0 RNA. J. Virol. 71:30053012.
77. WHO Expert Committee on Biological Standardization and Executive Board. 1998. Requirements for the Use of Animal Cells as In Vitro Substrates for the Production of Biologicals. WHO Technical Report Series no. 878. World Health Organization, Geneva, Switzerland.
78. Widholm, J. M. 1972. The use of fluorescein diacetate and phenosafranine for determining viability of cultured plant cells. Stain Technol. 47:189194.
79. Wood, D. J., and, P. D. Minor. 1990. Meeting report: use of diploid cells in production. Biologicals 18:143146.
80. Yanagi, M.,, B. J.,, S. U. Emerson, and, R. H. Purcell. 1996. Contamination of commercially available fetal bovine sera with bovine viral diarrhoea virus genomes: implications for the study of hepatitis C virus in cell cultures. J. Infect. Dis. 174:13241327.

Tables

Generic image for table
TABLE 1

Cell culture applications

Citation: Doblhoff-Dier O, Stacey G. 2006. Cell Lines: Applications and Biosafety, p 221-240. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch11
Generic image for table
TABLE 2

Common cell lines

Citation: Doblhoff-Dier O, Stacey G. 2006. Cell Lines: Applications and Biosafety, p 221-240. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch11
Generic image for table
TABLE 3

Viruses commonly used for validation studies

Citation: Doblhoff-Dier O, Stacey G. 2006. Cell Lines: Applications and Biosafety, p 221-240. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch11
Generic image for table
TABLE 4

Examples of techniques used for the measurement of cell growth and viability

Citation: Doblhoff-Dier O, Stacey G. 2006. Cell Lines: Applications and Biosafety, p 221-240. In Fleming D, Hunt D (ed), Biological Safety. ASM Press, Washington, DC. doi: 10.1128/9781555815899.ch11

This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error